Tempest Therapeutics (TPST) - Prakiraan volume dodolan
Tempest Therapeutics (TPST) develops targeted small-molecule drugs to modulate tumor immunity. The company's sales history and forecasts are based on the work of US laboratories and partnerships with clinics. The 0.00 level captures the current state of the metric. The business is currently preparing final tests for a liver cancer drug, seeking to attract external investors for joint financing.
Ringkesan rincian data analitis Tempest Therapeutics Inc (TPST)
- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi pasar:
- informasi kapitalisasi buku:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Tempest Therapeutics|TPST - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Tempest Tx|TPST - Gunggung kewajiban utang perusahaan|Utang marang nilai buku Tempest Therapeutics Inc|TPST - Gedhene kewajiban jangka dawa|Kewajiban jangka cendhak perusahaan Tempest Therapeutics|Indikator likuiditas cepet tempesttx.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
TPST - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Tempest Therapeutics|TPST - Nilai perusahaan marang bathi resik|Pangali Forward P/E Tempest Therapeutics, Inc.|TPST - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Tempest Therapeutics Inc|TPST - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Tempest Therapeutics|TPST - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan tempesttx.com|TPST - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Tempest Therapeutics
- data total pendapatan lan volume dodolan:
Analisis dhasar perusahaan:Tempest Therapeutics TPST
Institutional capital evaluates Tempest Therapeutics (TPST) through the lens of the potential monetization of its oncology pipeline. This indicator compares market capitalization with expected revenue to identify the degree of asset overvaluation. By analyzing the organization's projected sales, the investor sees a correlation between price and fundamental expectations. For a biotech company with transparent management and clear regulatory milestones, such a metric confirms the validity of the valuation, making the asset more predictable.
Pesaing wigati
Volume dodolan mangsa ngarep perusahaan ONC (BeiGene Ltd)|Prakiraan volume pendapatan perusahaan HALO|Prakiraan volume dodolan RVMD (Revolution Medicines, Inc.)|Ascentage Pharma Group International (AAPG) - Volume dodolan sing dikarepake perusahaan|CGON - Prakiraan pendapatan perusahaan|UroGen Pharma Corp (URGN) - Volume dodolan mangsa ngarep perusahaan|Bicara Therapeutics Inc. (BCAX) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan PSNL (personalis.com)|ERAS (Erasca) - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Delcath Systems Inc DCTH|Prakiraan pendapatan perusahaan YmAbs (YMAB)|Dodolan mangsa ngarep perusahaan Aura Corp|Candel Therapeutics, Inc. - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan ARAY (accuray.com)|SLS: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan ACTU (Actuate Therapeutics Inc.)|CTOR (Citius Oncology, Inc) - Volume dodolan mangsa ngarep perusahaan|HURA: Prakiraan volume pendapatan perusahaan|TARA (Protara Therapeutics) - Prakiraan volume dodolan|FATE: Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan WHWK|TCRX - Volume dodolan sing dikarepake perusahaan|Prakiraan pendapatan perusahaan Champions Oncology, Inc. CSBR|Pendapatan mangsa ngarep perusahaan XBIT|CEL-SCI Corp - Prakiraan volume dodolan|OSTX - Prakiraan volume dodolan|Radiopharm Theranostics (RADX) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan ARTV (Artiva Biotherapeutics)|ANL (Adlai Nortye Ltd) - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Veru Corporation VERU|Volume dodolan mangsa ngarep perusahaan XLO (Xilio Therapeutics, Inc.)|Prakiraan volume dodolan renovarobio.com (RENB)|Mural Oncology - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan KAPA (Kairos Pharma Limited)|OnKure - Prakiraan volume dodolan|Dodolan mangsa ngarep perusahaan CytoMed Therapeutics GDTC|CRIS: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Apollomics|Prakiraan pendapatan perusahaan Tharimmune|Advanced Biomed Corp (ADVB) - Dodolan mangsa ngarep perusahaan|Volume dodolan mangsa ngarep perusahaan GNPX (Genprex, Inc)|Prakiraan volume pendapatan perusahaan CLDI|Prakiraan pendapatan perusahaan Sunshine Biopharma SBFM|XBIO (Xenetic Biosciences Inc.) - Pendapatan sing dikarepake perusahaan|SLRX - Prakiraan pendapatan perusahaan|Dodolan mangsa ngarep perusahaan Purple Biotech Ltd PPBT|AONC (aoncology.com) - Volume dodolan mangsa ngarep perusahaan|BGNE: Prakiraan volume pendapatan perusahaan|CKPT (Checkpoint Therapeutics) - Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Elevation Oncology Inc. (ELEV)|Prakiraan volume dodolan ICAD|Prakiraan volume dodolan ikenaoncology.com (IKNA)|Prakiraan pendapatan perusahaan Notable Labs Inc. NTBL|VIRX: Prakiraan pendapatan perusahaan|MorphoSys AG - Prakiraan volume dodolan|nayabiosciences.com (NAYA) - Volume dodolan mangsa ngarep perusahaan|AAPGV: Prakiraan volume dodolan
